Fiera Capital Corp Sells 27,865 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Fiera Capital Corp lessened its stake in AtriCure, Inc. (NASDAQ:ATRCGet Rating) by 3.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 736,938 shares of the medical device company’s stock after selling 27,865 shares during the period. Fiera Capital Corp owned approximately 1.60% of AtriCure worth $51,239,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Captrust Financial Advisors grew its position in AtriCure by 5.6% in the 3rd quarter. Captrust Financial Advisors now owns 2,544 shares of the medical device company’s stock worth $177,000 after purchasing an additional 135 shares during the period. Arizona State Retirement System grew its position in AtriCure by 1.6% in the 3rd quarter. Arizona State Retirement System now owns 11,808 shares of the medical device company’s stock worth $821,000 after purchasing an additional 181 shares during the period. State Board of Administration of Florida Retirement System grew its position in shares of AtriCure by 1.2% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 17,859 shares of the medical device company’s stock valued at $1,242,000 after acquiring an additional 220 shares during the period. CNA Financial Corp grew its position in shares of AtriCure by 2.6% during the 3rd quarter. CNA Financial Corp now owns 15,600 shares of the medical device company’s stock valued at $1,085,000 after acquiring an additional 390 shares during the period. Finally, Manchester Capital Management LLC grew its position in shares of AtriCure by 1,351.4% during the 3rd quarter. Manchester Capital Management LLC now owns 508 shares of the medical device company’s stock valued at $35,000 after acquiring an additional 473 shares during the period. 93.28% of the stock is owned by institutional investors and hedge funds.

In other AtriCure news, insider Tonya Austin sold 1,626 shares of the business’s stock in a transaction on Wednesday, March 2nd. The shares were sold at an average price of $69.31, for a total value of $112,698.06. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 5,807 shares of company stock worth $394,645. Corporate insiders own 5.80% of the company’s stock.

ATRC stock traded down $2.07 during mid-day trading on Friday, hitting $51.93. The company had a trading volume of 521,835 shares, compared to its average volume of 198,255. The company has a market capitalization of $2.40 billion, a price-to-earnings ratio of 48.53 and a beta of 1.10. AtriCure, Inc. has a 12-month low of $51.39 and a 12-month high of $89.18. The company has a quick ratio of 2.78, a current ratio of 3.47 and a debt-to-equity ratio of 0.14. The company has a 50-day moving average price of $62.38 and a 200 day moving average price of $67.32.

AtriCure (NASDAQ:ATRCGet Rating) last announced its quarterly earnings results on Tuesday, February 15th. The medical device company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The company had revenue of $73.22 million during the quarter, compared to analysts’ expectations of $72.50 million. AtriCure had a negative return on equity of 11.96% and a net margin of 18.30%. During the same quarter in the previous year, the firm earned ($0.18) EPS. As a group, analysts expect that AtriCure, Inc. will post -1.09 EPS for the current year.

A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group cut their price objective on shares of AtriCure from $120.00 to $88.00 in a research report on Wednesday, February 16th. BTIG Research reissued a “buy” rating and set a $94.00 price objective on shares of AtriCure in a research report on Monday, March 14th. Needham & Company LLC reissued a “buy” rating and set a $79.00 price objective on shares of AtriCure in a research report on Thursday, February 24th. StockNews.com initiated coverage on shares of AtriCure in a research report on Thursday, March 31st. They set a “hold” rating for the company. Finally, Canaccord Genuity Group lowered their target price on shares of AtriCure from $120.00 to $88.00 and set a “buy” rating on the stock in a research note on Wednesday, February 16th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $91.33.

About AtriCure (Get Rating)

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.

Featured Articles

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRCGet Rating).

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.